Barclays lowered the firm’s price target on PTC Therapeutics to $25 from $26 and keeps an Equal Weight rating on the shares following the Q3 revenue miss.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PTCT:
- PTC Therapeutics falls 16% to $20.01 after below-consensus Q3 results
- PTC Therapeutics sees FY23 revenue $940M-$1.0B, consensus $938.32M
- PTC Therapeutics reports Q3 EPS ($1.76), consensus ($1.17)
- PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
- PTC Therapeutics signs royalty agreement with Royalty Pharma for Evrysdi